The last time we had a major run was when we rode the coattails of SAVA's P2 results for AD...we hit $31/share.
It sure would be nice if we could ride the coattails of RETA (now up over $50) since their drug was approved by the FDA for a rare disease that affects approx 5,000 people in the U.S.
Anavex's lead drug (A2-73) will complete their EXCELLENCE trial for a P2/3 by 2H 2023. If approved by the FDA, A2-73 would be targeting a rare disease that affects approx 17,000 people nationwide.
Even if we don't get a pop from the RETA approval this week, I'm still very confident that Anavex's share price will easily surpass $31/share once we get the results from the EXCELLENCE trial. (All comments are just my opinion, of course)
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066, a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer.
